Impact of stent designs of second-generation drug-eluting stents on long-term outcomes in coronary bifurcation lesions.

Abstract

We compared the long-term clinical outcomes of four different types of second-generation drug-eluting stents (DESs) in coronary bifurcation lesions. Clinical outcomes of different designs of second-generation DESs are not well known in bifurcation lesions. Patients who underwent percutaneous coronary intervention with second-generation DESs for coronary bifurcation lesion were enrolled from 21 centers in South Korea. A total of 2,526 patients was evaluated and divided into four treatment groups according to DES type: bioabsorbable polymer biolimus-eluting stent (BP-BES group, n=514), platinum chromium everolimus-eluting stent (PtCr-EES group, n=473), cobalt nickel zotarolimus-eluting stent (CoNi-ZES group, n=736), or cobalt chromium everolimus-eluting stent (CoCr-EES group, n=803). Primary outcome was target lesion failure (TLF, defined as a composite of cardiac death, target vessel myocardial infarction, or target lesion revascularization). Inverse probability of treatment weighting (IPTW) was performed to reduce selection bias and potential confounding factors. For 5 years of follow-up, the rates of TLF among the four DES groups were not significantly different (6.2% for BP-BES group, 8.2% for PtCr-EES group, 6.5% for CoNi-ZES group, and 8.6% for CoCr-EES group, p=.434). The results were consistent after IPTW adjustment (6.8, 8.4, 6.0, and 7.5%, respectively, p=.554). In subgroup analysis, the similarity of long-term outcomes among the four different types of second-generation DES was consistent across subgroups regardless of side branch treatment (p for interaction=.691). There seems to be no significant difference in long-term clinical outcomes among patients who received different types of second-generation DES for coronary bifurcation lesion.